The Colon Carcinoma drugs in development market research report provides comprehensive information on the therapeutics under development for Colon Carcinoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Colon Carcinoma. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Colon Carcinoma - Drugs In Development, 2023

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Colon Carcinoma and features dormant and discontinued products.

GlobalData tracks 39 drugs in development for Colon Carcinoma by 34 companies/universities/institutes. The top development phase for Colon Carcinoma is preclinical with 29 drugs in that stage. The Colon Carcinoma pipeline has 34 drugs in development by companies and five by universities/ institutes. Some of the companies in the Colon Carcinoma pipeline products market are: Harbour BioMed (Guangzhou), KAHR medical and Eucure (Beijing) Biopharma.

The key targets in the Colon Carcinoma pipeline products market include Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9), Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1), and Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4).

The key mechanisms of action in the Colon Carcinoma pipeline product include Tumor Necrosis Factor Receptor Superfamily Member 9 (4-1BB Ligand Receptor or T Cell Antigen 4-1BB Homolog or T Cell Antigen ILA or CD137 or TNFRSF9) Agonist with three drugs in IND/CTA Filed. The Colon Carcinoma pipeline products include five routes of administration with the top ROA being Intravenous and 11 key molecule types in the Colon Carcinoma pipeline products market including Monoclonal Antibody, and Small Molecule.

Colon Carcinoma overview

Colon carcinoma is a type of cancer that affects the large intestine, which includes the colon and the rectum. It is one of the most common cancers worldwide and can cause symptoms such as blood in the stool, weight loss, and fatigue. Colon carcinoma usually develops from benign growths called polyps that form on the inner lining of the colon or rectum. Some of these polyps can become malignant over time and invade the surrounding tissues or spread to other parts of the body. The risk factors for colon carcinoma include older age, diet, obesity, smoking, alcohol use, inflammatory bowel disease, and genetic disorders. Colon carcinoma can be diagnosed by biopsy during a colonoscopy or sigmoidoscopy, and treated by surgery, radiation therapy, chemotherapy, or targeted therapy depending on the stage and location of the tumor. Screening tests can help detect and remove polyps before they become cancerous and reduce the mortality from colon carcinoma.

For a complete picture of Colon Carcinoma’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.